Notice
10 Sep 2025
immunotoxins, patent, exclusive license, nih, cancer treatment, health, biotechnology
🧬Prospective Exclusive Patent License for Cancer Treatment Innovations
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an NCI Exclusive Patent License to practice the inventions embodied in the patents listed in the Supplementary Information section of this notice to Lysin Therapeutics, Inc. (Lysin), a company located in Silver Spring, MD.
Learn More